Anna Richo joins Illumina's Board of Directors

Anna Richo joins Illumina's Board of Directors

Ms. Richo brings more than 30 years of global legal, compliance, and regulatory experience to Illumina's Board

Illumina, Inc. (NASDAQ: ILMN) announced today that Anna Richo has joined the company's Board of Directors following shareholder approval of the director slate at the company's May 16, 2024 annual meeting. Ms. Richo currently serves as Corporate Senior Vice President, Strategic Advisor to the General Counsel and CEO at Cargill, Inc. a global food production and agricultural company.

Ms. Richo brings more than 30 years of regulated-industry experience as an attorney and legal executive, with extensive experience in compliance and business ethics, intellectual property, and corporate litigation. She formerly served as Corporate Senior Vice President, General Counsel, Chief Compliance Officer, and Corporate Secretary at Cargill, where she oversaw the company's corporate governance, global ethics and compliance, global security, global government relations, law, and shareholder relations functions.

Prior to joining Cargill, Ms. Richo was Executive Vice President and General Counsel at UCB, a biopharmaceutical company based in Belgium . She also served as Senior Vice President and Chief Compliance Officer at Amgen, a global biotechnology company, and as Chief Litigation Counsel, Associate General Counsel, and Vice President of Law at Baxter Healthcare.

"I am thrilled to welcome Anna to our Board of Directors," said Jacob Thaysen , CEO of Illumina. "In today's evolving business and regulatory environment, her extensive global legal, compliance, and regulatory experience, including at biotechnology, biopharmaceutical, and medtech companies, will enhance our evaluation and understanding of the risks and opportunities associated with Illumina's expanding worldwide operations."

Ms. Richo also serves as a member of Exelon's Board of Directors, as a member of the Cargill Foundation Board of Directors, on the Board of Trustees for DePaul University , and on the Children's Minnesota Governance Board.

Ms. Richo holds a B.S. in Industrial and Labor Relations from Cornell University and a J.D. from DePaul University College of Law.

About Illumina

Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit www.illumina.com and connect with us on X(Twitter) , Facebook , LinkedIn , Instagram , TikTok , and YouTube .

Investors:
Salli Schwartz
858-291-6421
IR@illumina.com

Media:
Bonny Fowler
740-641-5579
PR@illumina.com

Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/anna-richo-joins-illuminas-board-of-directors-302150329.html

SOURCE Illumina, Inc.

News Provided by PR Newswire via QuoteMedia

ILMN:US
The Conversation (0)
Illumina launches latest chemistry across most popular mid-throughput sequencers, enabling higher quality and greater speed for customers at lower cost

Illumina launches latest chemistry across most popular mid-throughput sequencers, enabling higher quality and greater speed for customers at lower cost

Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, announced that it has completed integration of its latest chemistry, XLEAP-SBS â„¢ into all reagents for its NextSeq â„¢ 1000 and NextSeq 2000 next-generation sequencing (NGS) instruments. "We are excited... Keep Reading...
Illumina Board of Directors approves spin-off of GRAIL; declares spin-off dividend of GRAIL shares

Illumina Board of Directors approves spin-off of GRAIL; declares spin-off dividend of GRAIL shares

"When-issued" trading expected to begin on or about June 12, 2024 Record date for distribution of GRAIL shares will be June 13, 2024 Distribution date for GRAIL shares anticipated to be June 24, 2024 Illumina, Inc. (NASDAQ: ILMN) today announced that its Board of Directors has approved the... Keep Reading...
Illumina appoints Everett Cunningham Chief Commercial Officer

Illumina appoints Everett Cunningham Chief Commercial Officer

Cunningham previously served as CCO for Exact Sciences and brings more than 20 years of commercial leadership across healthcare tech, life sciences, and pharma - Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced the appointment of... Keep Reading...
Illumina drives genomic testing as standard of care in oncology through collaborative research presented at ASCO

Illumina drives genomic testing as standard of care in oncology through collaborative research presented at ASCO

Studies presented represent key focus areas, including building evidence for clinical utility of comprehensive genomic profiling; overcoming market access barriers, and progressing the whole-genome approach for MRD Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based... Keep Reading...
Illumina releases 2023 Corporate Social Responsibility Report

Illumina releases 2023 Corporate Social Responsibility Report

Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today published its fifth annual Corporate Social Responsibility (CSR) Report. The report highlights the company's ongoing commitments and progress made in 2023 toward advancing human health by serving... Keep Reading...

Latest Press Releases

Related News